Crohn’s Disease | Treatment Algorithms: Claims Data Analysis | Adult | US | 2025

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of treatment is to induce and maintain remission. Treatment of adult CD typically begins with safe, albeit less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. This scenario is changing, as more physicians prescribe biologics as first-line therapy for recently diagnosed CD. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors, including infliximab, adalimumab, and their biosimilars, and non-TNF biologics (e.g., Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara) have a relatively constant patient share. Later-to-market therapies from AbbVie—the JAK inhibitor Rinvoq and the IL-23 inhibitor Skyrizi—further increase the competition. This report offers insight on current prescribing trends in the treatment of adult CD, based on U.S. real-world claims data.

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult CD patients?
• How have Skyrizi and Rinvoq been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of adult CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of adult CD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Janssen, AbbVie, Takeda, UCB

Key drugs: Entyvio, Rinvoq, Remicade, infliximab biosimilars, Humira, adalimumab biosimilars, Skyrizi, Stelara

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses